Tirzepatide — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Tirzepatide

Also known as: Mounjaro, Zepbound, LY3298176, twincretin, dual GIP/GLP-1 receptor agonist

Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist; first-in-class incretin mimetic

Research chemicalLast updated: November 4, 2026Based on 34 peer-reviewed studies

What it is

Tirzepatide is the active ingredient in Mounjaro (type 2 diabetes) and Zepbound (obesity), FDA-approved drugs that produce significant weight loss and blood sugar control. It works by activating two hormone pathways at once to reduce appetite and improve insulin sensitivity. Prescription-only; also being studied for heart failure and sleep apnea.

The scientific side

Tirzepatide is a first-in-class dual agonist at receptors for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) (PMID 38388874; PMID 37070418). By simultaneously activating both incretin pathways, it improves glycemic control, reduces appetite and food intake, promotes weight loss, and exerts pleiotropic cardiometabolic effects (PMID 41923370; PMID 38994609). Population pharmacokinetic modeling shows tirzepatide follows a two-compartment model with first-order absorption and elimination, a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. Mechanistic studies suggest tirzepatide increases fat oxidation and reduces calorie intake without meaningfully impacting metabolic adaptation in humans. Additional mechanisms under investigation include anti-inflammatory effects (reduction of hsCRP and IL-6), modulation of gut microbiota and bile acid metabolism, improvement of islet cell function and insulin sensitivity, enhancement of endothelial nitric oxide synthase activity, suppression of pro-inflammatory cytokines, and improvement of lipid profiles.

Class: Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist; first-in-class incretin mimetic

Legal & regulatory status

US FDA

FDA-approved (initial U.S. approval 2022) as Mounjaro, as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes, and as Zepbound, with a reduced-calorie diet and increased physical activity, to…

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification